COVID-19 breakthrough infection and mortality among the vaccinated population : a meta-analysis / Alfonso IV B. Alino, Klarren Rae V. Cabang, Jazzel L. Cabiles, Mary Grace L. Cacapit, Thea Amabelle P. Calibuso, Katleen C. Carlos, Marjorie Ann Lorirene A. Cordero, Chrislia M. Cruz, Jhen Ruselle D. Cruz, Aljon Miguel E. Dela Cruz and Paola Noreen A. Dela Merced.

Contributor(s):

Publication details: Fairview, Quezon City: Department of Community and Family Medicine, FEU-NRMF, 2022.Description: illustrations, tables; 28 cmContent type:

text

Media type:

unmediated

Carrier type:

volume

Subject(s):

LOC classification:

MCFM 2022 0013

Summary: Abstract: The novel coronavirus which appeared in Wuhan, China last December 2019, had caused a worldwide pandemic that had been sweeping the globe for more than a year. To help reduce the morbidity and mortality rate linked with COVID-19, mass immunization had been implemented all over the world. However, after receiving the first and second doses of the COVID-19 vaccines, incidences of breakthrough infections and fatality had been observed. Currently, there is still limited knowledge on COVID-19 vaccination and its outcomes; a meta-analysis was conducted to determine the COVID-19 mortality and morbidity in terms of breakthrough infection, severity of illness and hospitalizations after COVID-19 immunization. The researchers searched articles from different databases including PubMed, ScienceDirect and Google Scholar search engine from January 2020 to April 2022. A total of 11 articles were included in the final analyses which met the inclusion criteria. The breakthrough infections among the population with a single dose of COVID-19 vaccine revealed an odds ratio of 0.22 (95%) Cl:0.21, 0.22, I2 = 97%), 0.55 (95% CI: 0.53, 0.58, I2 =100%) for hospitalization and 0.07 (95% CI: 0.06, 0.07, I2 = 99%) for mortality. Among the total population that received the second dose of COVID-19 vaccines, the results reported an odds ratio of 0.05 (95% CI: 0.05, 0.05, I2 =89%) for the breakthrough infections, 0.12(95% CI:0.11, 0.13, I2 =97%) for hospitalization and 0.02 (95% CI: 0.02, 0.02, I2 =97%) for mortality. These results both indicated that SARS-CoV-2 vaccinations had shown to be effective in reducing breakthrough infections, hospitalizations and death caused by the virus over the world. In this study, people who received the second dose of the Pfizer vaccine had the lowest rate of breakthrough infections (0.17%) and mortality (0.002%) and those received two doses of AztraZeneca vaccine had the lowest rate of hospitalizations (0.06%).

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Call number	Status	Date due	Barcode
Room Use	Far Eastern University - Nicanor Reyes Medical Foundation Theses	MCFM 2022 0013 (Browse shelf(Opens below))	Available		T002395

Includes bibliographical references.

Abstract: The novel coronavirus which appeared in Wuhan, China last December 2019, had caused a worldwide pandemic that had been sweeping the globe for more than a year. To help reduce the morbidity and mortality rate linked with COVID-19, mass immunization had been implemented all over the world. However, after receiving the first and second doses of the COVID-19 vaccines, incidences of breakthrough infections and fatality had been observed. Currently, there is still limited knowledge on COVID-19 vaccination and its outcomes; a meta-analysis was conducted to determine the COVID-19 mortality and morbidity in terms of breakthrough infection, severity of illness and hospitalizations after COVID-19 immunization. The researchers searched articles from different databases including PubMed, ScienceDirect and Google Scholar search engine from January 2020 to April 2022. A total of 11 articles were included in the final analyses which met the inclusion criteria. The breakthrough infections among the population with a single dose of COVID-19 vaccine revealed an odds ratio of 0.22 (95%) Cl:0.21, 0.22, I2 = 97%), 0.55 (95% CI: 0.53, 0.58, I2 =100%) for hospitalization and 0.07 (95% CI: 0.06, 0.07, I2 = 99%) for mortality. Among the total population that received the second dose of COVID-19 vaccines, the results reported an odds ratio of 0.05 (95% CI: 0.05, 0.05, I2 =89%) for the breakthrough infections, 0.12(95% CI:0.11, 0.13, I2 =97%) for hospitalization and 0.02 (95% CI: 0.02, 0.02, I2 =97%) for mortality. These results both indicated that SARS-CoV-2 vaccinations had shown to be effective in reducing breakthrough infections, hospitalizations and death caused by the virus over the world. In this study, people who received the second dose of the Pfizer vaccine had the lowest rate of breakthrough infections (0.17%) and mortality (0.002%) and those received two doses of AztraZeneca vaccine had the lowest rate of hospitalizations (0.06%).

Thesis - Department of Community & Family Medicine

There are no comments on this title.

to post a comment.